考虑标度的加型一致性模糊判断矩阵的排序方法

通过实例说明相关文献中加型一致性模糊判断矩阵排序方法的参数取值存在的问题,分析出该问题是由于其公式证明中没有区分标度导致的,指出其结论适用于0～1标度的加型一致性模糊判断矩阵.然后,重新证明了0.1～0.9标度下的加型一致性模糊判决矩阵的排序方法和相关结论.最后,定义了广义模糊标度,并给出广义模糊标度下加型一致性模糊判断矩阵的排序方法和相关结论,使得相关文献中排序方法和相关结论实现形式上的统一.     

基因编辑婴儿的伦理、法律和社会蕴含

 同试管婴儿、克隆人、商业化代孕、干细胞治疗等医疗新技术引发的伦理争议相比，贺建奎基因编辑婴儿事件引发的关注更大、社会反响更为猛烈。探讨贺建奎基因编辑婴儿事件引发国际国内热议的原因，讨论了基因编辑婴儿的伦理、法律和社会蕴含。建议明确界定基因编辑技术的适用对象和范围，建立健全新型医疗技术临床应用的伦理审查和监管体系，提升全社会的伦理意识。     

湍流大小尺度涡量方程组及其封闭

利用流体大小尺度 (LSS)方程组推导出湍流大小尺度涡量 (LSSV)方程组 ,给出两个关于湍流大小尺度涡量的命题 ,从而得到湍流封闭大小尺度涡量 (CLSSV)方程组。同时 ,对近程相互作用命题进行了推广。     

算法的相关性变换与划分带个数的关系

使用相关性变换法，划分并映射循环算法到具有固定尺寸的Ｓｙｓｔｏｌｉｃ阵列。下标集合被划分成若干条带，划分带的条数与变换后的Ｓｙｓｔｏｌｉｃ阵列算法的执行时间成正比。指出了Ｍｏｌｄｏｖａｎ给出的计算划分带条数的公式有很大局限性，给出了由空间变换计算划分带条数的方法。     

植物基因环境效应启动子

植物的生长发育受到光照、温度、水分及氧等环境因素的影响，根据对不同环境的响应，植物基因的启动子主要可以分为光效应启动子，温度效应启动子和水效应启动子。在这些启动子中，除了含有基本启动子外，还存在一些特异的顺式调节元件，这些顺式调节元件在特异表达中发挥重要作用。     

大鼠肝ADAMs种类鉴定及肝再生过程中ADAMsmRNA差异分析

以 2 / 3肝切除 (patialhepatectomy ,PH)大鼠为材料 ,利用PT -PCR技术 ,通过ADAMs通用引物初步分析了肝脏中ADAMs种类及PH后恢复 4h和 36h时ADAMsmRNA差异。结果表明 :PH后不同恢复时间ADAMsmRNA的扩增谱带没有差异 ,但扩增谱带的强弱有变化 ;cDNA克隆和测序分析表明 ,大鼠肝脏有ADAM15和ADAM 19mRNA同源序列。     

噬菌体展示禽流感病毒抗原变异性基因片段文库的构建

构建T7噬菌体展示禽流感病毒抗原变异性基因片段文库. 首先， 从Gene Bank中查找筛选禽流感病毒抗原变异性基因, 将其截短、 修饰、 简并后得到禽流感病毒抗原变异性基因微阵列. 其次， 将合成的禽流感病毒抗原变异性基因片段文库扩增、 酶切, 链接到双酶切后的T7噬菌体载体基因上, 构成重组噬菌体DNA. 最后， 重组噬菌体DNA经体外包装和扩增, 得到T7噬菌体展示文库, 并进行T7噬菌体展示文库滴度、 重组率和免疫活性测定. 实验结果表明, 从Gene Bank中查找、 筛选、 剪切和修饰共获得96 258条序列构建T7噬菌体展示文库, 原始文库滴度为3.6×107个菌落/mL, 重组率大于90%. 用禽流感病毒H5N1抗体进行捕获, 经聚合酶链式反应(PCR)鉴定, 得到理想目的条带, 证明噬菌体表面展示蛋白具有抗原活性, 可用于禽流感病毒感染患者的快速检测及抗原表位筛选.     

Specific anti-tumor effect induced by attenuated Salmonella typhimurium vaccine expressing extracellular region of vascular endothelial growth factor receptor 2

The purposes of this research were to study the stable expression of exogenous gene encoding therapeutic protein in attenuated Salmonella typhimurium, observe the metabolism of oral gene vaccine carried by attenuated Salmonella typhimurium in BALB/c mouse, and investigate the feasibility of prevention and treatment of tumors by the recombinant bacteria. Recombinant plasmid pcDNA3.1 VEGFR2(n1-7) was transformed into competent attenuated Salmonella typhimurium SL3261 to develop oral DNA vaccine SL3261-pcDNA3.1 VEGFR2(n1-7). To observe whether the exogenous gene can be expressed in the recombinant bacteria, PCR was performed to amplify the CMV promoter of the eukaryotic expression vector as the proof of stable expression of exogenous protein; transmission elec- tron microscopy (TEM) was applied to observe the morphology of the recombinant bacteria to confirm that the exogenous gene has no impact on the growth of the bacteria, and then BALB/c mice were immunized with the gene vaccine. After inoculation of the gene vaccine, the recombinant bacteria SL3261 could be detected in the tissues such as small intestine, colon, liver and spleen. And then, mice in each group were challenged with tumor cells. The results of animal experiment showed that tumor growth of the mice in experimental group was inhibited and survival time of immunized mice was prolonged compared with control groups. A higher lymphocyte infiltration in tumors from animals treated with DNA vaccine was observed. Immunohistochemical analysis of tumor samples revealed an en- hanced accumulation of CD8 cytotoxic T lymphocytes, as well as an increase in CD4 cells in the tumors of animals treated with the oral gene vaccine compared to tumors from control group mice. Ultrastructure of the tumor tissue showed that tumor cells in the samples of the immunized mice were well-differentiated. Our research confirmed that the exogenous gene can be stably expressed in the attenuated Salmonella typhimurium and has no impact on the growth of the recombinant bacteria; the exogenous gene can de delivered to the host by attenuated Salmonella typhimurium to produce anti-tumor effect with no obvious cytotoxity to the host. In this study, it is established that attenuated Salmonella typhimurium could be used as a vector for oral gene vaccine, and our study provided a theoretical basis for the body distribution and the metabolism of the recombinant bacteria. This strategy may provide a simple, safe and effective way for the prevention and treatment of tumors.     

The human genome and understanding of common disease: present and future technologies

The study of candidate genes over the past three decades has yielded notable successes in common-disease genetics. During this time, however, interpretation of genetic association studies has been hampered by the use of clinical cohorts of inadequate power and insufficient information on genetic variation in candidate genes. The unavailability of highthroughput and low-cost genotyping technologies has also limited the scope of complex-disease genetic studies. More recently, however, the sequencing and characterization of variation within the human genome has revolutionized genetic studies and enabled full genome-wide scans for genes associated with disease. The identification of disease-associated (causative) genes has illuminated disease mechanisms. The translation of this knowledge into direct clinical benefit in diagnosis, prognosis and therapy for an individual’s disease still remains a challenge. Received 11 September 2006; received after revision 17 December 2006; accepted 18 January 2007